Fennec Pharmaceuticals Inc
FENC
NASDAQ
Biotechnology
$11.72
USD
-0.34 (-2.82%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $420.32M
Volume 106.9K
Revenue
$51.00M
TTM
+65.0%
YoY
Gross Margin
92%
TTM
+2.2%
YoY
Net Income
$-8.38M
TTM
+42.0%
YoY
Operating Cash Flow
$-5.78M
TTM
+64.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 8.8 | 9.7 | 12.5 | 13.8 | 15.1 |
YoY Growth | -65.5% | +32.9% | +78.7% | +73.8% | +72.6% |
Cost of Revenue | 0.4 | 1.0 | 0.7 | 1.8 | 0.6 |
Gross Profit | 8.4 | 8.7 | 11.8 | 12.0 | 14.5 |
Selling, General & Administrative | 9.1 | 11.3 | 12.0 | 14.5 | 14.6 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 9.2 | 11.4 | 12.0 | 14.6 | 14.7 |
Operating Income | -0.8 | -2.7 | -0.2 | -2.6 | -0.1 |
EBITDA | -0.8 | -2.8 | -0.2 | -2.6 | -0.1 |
Other Income / Expense | -0.0 | 0.0 | -0.0 | -2.0 | -0.0 |
Total Other Income / Expense | -0.4 | -0.4 | -0.4 | -2.1 | 0.3 |
Income Before Income Taxes | -1.2 | -3.2 | -0.6 | -4.7 | 0.2 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 |
Net Income | -1.2 | -3.2 | -0.6 | -4.8 | 0.2 |
Consolidated Net Income / Loss | -1.2 | -3.2 | -0.6 | -4.8 | 0.2 |
Net Income Attributable to Common Shareholders | -1.2 | -3.2 | -0.6 | -4.8 | 0.2 |
Basic EPS | -$0.04 | -$0.11 | -$0.02 | -$0.15 | $0.01 |
Diluted EPS | -$0.04 | -$0.11 | -$0.02 | -$0.15 | $0.01 |
Basic Shares Outstanding | 27.6M | 27.7M | 27.9M | 31.2M | 34.3M |
Diluted Shares Outstanding | 27.6M | 27.7M | 27.9M | 31.2M | 35.5M |